



VENMAX

DRUGS AND PHARMACEUTICALS LIMITED.

Venmax Drugs and Pharmaceuticals Ltd,
F.No. 1-140, Rajeswari Ware House,
Opposite to Sri Convention, Kompally,
Quthbullapur, Hyderabad,
Machhal Dist-500014, Telangana.
E-mail: venmaxdrugs@gmail.com

To,
The Secretary,
BSE Limited,
Phiroze Jeejeebhoy,
Towers, Dalal Street,
Fort, Mumbai - 400 001.

Date: 28.05.2022

Scrip code: 531015

Dear Sir/Madam,

Sub: Unaudited Financial Results for the Quarter ended 30th June, 2021:

Pursuant to Reg.30 and 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we wish to inform you that the Board of Directors of the Company at its meeting held on 19th July, 2021 had inter-alia,

- (i) Approved the Un Audited financial results of the Company for the quarter ended 30th June, 2021 and Limited Review Report of the Auditors thereon.

This is for your information and record.

Thanking you,

Yours Faithfully,

For Venmax Drugs and Pharmaceuticals Limited

Nocka
Krishnaiah
N. Krishnaiah
Director
DIN:07279009





Independent Auditor's Report on Quarterly Unaudited financial Results of M/s VENMAX DRUGS AND PHARMACEUTICALS LIMITED pursuant to Regulation 33 of the SEBI(Listing and Obligations and Disclosure requirements) Regulations, 2015.

To the Board of Directors of **VENMAX DRUGS AND PHARMACEUTICALS LIMITED**

We have reviewed the accompanying statement of unaudited financial results of **VENMAX DRUGS AND PHARMACEUTICALS LIMITED** ('The Company') for the quarter ended June 30, 2021. This statement is the responsibility of the company's management and has been approved by the board of directors. Our responsibility is to issue a report on these financial statements based on our review.

We conducted our review of the Statement in accordance with the Standards on Review Engagement (SRE) 2410 'Review of Interim Financial Information Performed by the Independent Auditor of the entity' issued by the Institute of Chartered Accountants of India. This Standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial results are free from material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly we do not express an audit opinion.

Based on our review conducted as stated above, nothing has come to our attention that causes us to believe that the accompanying statement, prepared in accordance with the recognition and measurement principles laid down in the applicable Indian accounting standards specified under section 133 of the Companies Act, 2013, read with relevant rules issued there under and other recognized accounting principles and policies has not disclosed the information required to be disclosed in terms of the regulation 33 of the SEBI (Listing Obligations and disclosure requirements) regulations, 2015 including the manner in which it is to be disclosed or that it contains any material misstatements.

For **NSVR & Associates LLP**
Chartered Accountants
FRN: 008801S/S200067


Suresh Gannamani

Partner

Membership No.226870

UDIN: 22226870ANQJUK3778



Place: Hyderabad

Date: 28/05/2022



VENMAX

DRUGS AND PHARMACEUTICALS LIMITED.

Venmax Drugs and Pharmaceuticals Ltd.
H.No. 1-140, Rajeeswari Ware House,
Opposite to Sri Conventon, Kompally,
Quthbullapur, Hyderabad,
Medchal Dist-500014, Telangana.
E-mail: venmaxdrugs@gmail.com

VENMAX DRUGS AND PHARMACEUTICALS LIMITED
(CIN: L24230TG1988PLC009102)
Extract of Un-audited financial results for the Quarter Ended 30.06.2021

Particulars	Quarter ended	Quarter ended	Quarter ended	Year ended
	30.06.2021	31.03.2021	30.06.2020	31.03.2021
	Un-Audited	Audited	Un-Audited	Audited
Total Income	0.90	18.14	6.95	34.93
Net Profit before Tax, Exceptional and/or Extraordinary items)	(3.41)	3.10	(6.53)	(16.18)
Net Profit before tax (after Exceptional and/or Extraordinary items)	(3.41)	3.10	(6.53)	(16.18)
Net Profit after tax (after Exceptional and/or Extraordinary items)	(3.42)	3.08	(6.55)	(16.25)
Total Comprehensive Income (Comprising Profit after tax and Other Comprehensive Income (after tax))	(3.42)	3.08	(6.55)	(16.25)
Paid up Equity Share Capital (Rs.10/- Per Equity Share)	523.89	523.89	523.89	523.89
Reserves (excluding Revaluation Reserve as shown in the Balance Sheet)	-	-	-	(786.28)
Earnings Per Share (of Rs.10/- each) (Not Annualised)	-0.07	0.06	-0.12	-0.31
a) Basic	-0.07	0.06	-0.12	-0.31
b) Diluted	-0.07	0.06	-0.12	-0.31

The above financial results as recommended by the Audit Committee were considered and approved by the Board of Directors at their meeting held on 19th July, 2021.

Note : The above is an extract of the detailed format of Quarterly Financial Results filed with the Stock Exchange under Regulations 33 of the SEBI (Listing and Other Disclosure Requirements) Regulations, 2015. The full format of the Quarterly Financial Results are available on company's website and the stock exchange's websites, www.nseindia.com and www.bseindia.com.

Place : Hyderabad
Date : 19/07/2021

VENMAX DRUGS & PHARMACEUTICALS LTD.
MANGALAM

For Venmax Drugs and Pharmaceuticals Limited
Managing Director
Raj Kumar Rai
DIN: 0009207

VENMAX DRUGS AND PHARMACEUTICALS LIMITED				
ILNo.1-146, Rajawari Ware House, Opposite to Sri Convention, Koonpally, Quthbullapur Hyderabad Rangareddy TG 506055 (CIN: L24230TG1988PLC009102)				
(in Rs Lakhs)				
Statement Of Un-Audited Results For The Quarter Ended 30 June 2021				
Particulars	Quarter ended June 30,2021	Quarter ended March 31,2021	Quarter ended June 30,2020	Year ended March 31,2021
	(Un Audited)	(Audited)	(Un Audited)	(Audited)
Income				
Revenue from operations	-	-	6.95	16.79
Total Revenue from operations	-	-	6.95	16.79
Other income	-	18.14	-	18.14
Total Income	-	18.14	6.95	34.93
Expenses				
Raw Material Consumed	-	-	4.83	7.86
Changes in inventories of work-in-progress	-	5.74	4.19	21.58
Employee benefits	0.30	1.20	1.86	6.27
Finance cost	-	(0.00)	-	-
Depreciation	0.23	0.26	0.26	1.03
Other expenses	2.88	7.85	2.34	14.37
Total Expenses	3.41	15.05	13.48	51.11
Profit before tax	(3.41)	3.10	(6.53)	(16.18)
Tax expense				
(1) Current tax	-	-	-	-
(2) Deferred tax	0.01	0.02	0.02	0.07
Net Profit for the Period	(3.42)	3.08	(6.55)	(16.25)
Other comprehensive income (OCI)				
(a) (i) Items that will not be reclassified to profit or loss	-	-	-	-
(ii) Tax on items that will not be reclassified to profit or loss	-	-	-	-
(b) (i) Items that will be reclassified to profit or loss	-	-	-	-
(ii) Income tax relating to items that will be reclassified to profit or loss	-	-	-	-
Total Other Comprehensive income	-	-	-	-
Total Comprehensive income	(3.42)	3.08	(6.55)	(16.25)
Paid-up Equity Share Capital (Rs. 10/- per Equity Share)	523.89	523.89	523.89	523.89
Other Equity	-	-	-	(802.52)
Earnings per equity share (Face value of Rs.10/- each)				
(1) Basic	(0.07)	0.06	(0.12)	(0.31)
(2) Diluted	(0.07)	0.06	(0.12)	(0.31)
Notes				
a) The financial results of the company have been prepared in accordance with Indian Accounting Standards (Ind AS) notified under the Companies (Indian Accounting standards) Rules, 2015 as amended by the Companies (Indian Accounting Standards) (Amendment) rules 2016.				
b) The above Financial results recommended by the Audit Committee are considered and approved by the Board of Directors at their meeting held on 19th July, 2021				
c) The above statement have been prepared to the extent applicable, in accordance with the companies (Indian Accounting Standards) Rules, 2015 (Ind AS), prescribed under Section 133 of the Companies Act, 2013 and other recognised Accounting Practices and Policies adopted by the Company w.e.f.01.04.2017. The financial results of the previous periods duly complied with Ind AS have not been subjected to review or audit, however, the Management has exercised necessary diligence to ensure that the financial results provide a true and fair view of the Company's affairs.				
d) The Statutory Auditors of the Company have carried out "Limited Review" of the above unaudited financial results and their Report has been placed before the Board at the said Meeting as required under Regulation 33 of SEBI (LODR) Regulations, 2015				
e) Estimation uncertainty relating to the global health pandemic on COVID-19 The management has considered the possible errors, if any, that may result from the pandemic relating to LAYERS - 19 on the carrying amounts of trade receivables & inventories. In assessing the recoverability of receivables, the Company has considered internal and external information upto the date of approval of these financial results including credit reports and economic forecasts. The Company has performed sensitivity analysis on the assumptions used and based on current indicators of future economic conditions, the Company expects to recover the carrying amount of these assets. The impact of the global health pandemic may be different from that estimated as at the date of approval of these financial results and the Company will continue to monitor the situation.				
f) The Company is engaged in activities of trading of bulk drugs, intermediates and biotech products. Hence Segment reporting is not applicable.				

Date: 19/07/2021
Place: Hyderabad



For Venmax Drugs & Pharmaceuticals Limited

Raj Kumar Rai
Managing Director
DIN: 0009207